AT392904T - A pharmaceutical composition for immunostimulation and for preparation of vaccines containing an antigen, and an immunogenic oligodeoxynucleotide as adjuvants and a polycationic polypeptide - Google Patents

A pharmaceutical composition for immunostimulation and for preparation of vaccines containing an antigen, and an immunogenic oligodeoxynucleotide as adjuvants and a polycationic polypeptide

Info

Publication number
AT392904T
AT392904T AT01903625T AT01903625T AT392904T AT 392904 T AT392904 T AT 392904T AT 01903625 T AT01903625 T AT 01903625T AT 01903625 T AT01903625 T AT 01903625T AT 392904 T AT392904 T AT 392904T
Authority
AT
Austria
Prior art keywords
immunostimulation
adjuvants
antigen
preparation
pharmaceutical composition
Prior art date
Application number
AT01903625T
Other languages
German (de)
Inventor
Karen Lingnau
Frank Mattner
Walter Schmidt
Max Birnstiel
Michael Buschle
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT1292000A priority Critical patent/AT409085B/en
Application filed by Intercell Ag filed Critical Intercell Ag
Priority to PCT/EP2001/000087 priority patent/WO2001054720A1/en
Publication of AT392904T publication Critical patent/AT392904T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
AT01903625T 2000-01-28 2001-01-05 A pharmaceutical composition for immunostimulation and for preparation of vaccines containing an antigen, and an immunogenic oligodeoxynucleotide as adjuvants and a polycationic polypeptide AT392904T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT1292000A AT409085B (en) 2000-01-28 2000-01-28 A pharmaceutical composition for immunomodulation and preparation of vaccines
PCT/EP2001/000087 WO2001054720A1 (en) 2000-01-28 2001-01-05 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants

Publications (1)

Publication Number Publication Date
AT392904T true AT392904T (en) 2008-05-15

Family

ID=3635970

Family Applications (2)

Application Number Title Priority Date Filing Date
AT1292000A AT409085B (en) 2000-01-28 2000-01-28 A pharmaceutical composition for immunomodulation and preparation of vaccines
AT01903625T AT392904T (en) 2000-01-28 2001-01-05 A pharmaceutical composition for immunostimulation and for preparation of vaccines containing an antigen, and an immunogenic oligodeoxynucleotide as adjuvants and a polycationic polypeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT1292000A AT409085B (en) 2000-01-28 2000-01-28 A pharmaceutical composition for immunomodulation and preparation of vaccines

Country Status (12)

Country Link
US (1) US20020197269A1 (en)
EP (1) EP1251871B1 (en)
JP (1) JP2003520824A (en)
AR (1) AR026940A1 (en)
AT (2) AT409085B (en)
AU (1) AU784403B2 (en)
CA (1) CA2396884A1 (en)
DE (1) DE60133717T2 (en)
ES (1) ES2304376T3 (en)
PE (1) PE12172001A1 (en)
UY (1) UY26555A1 (en)
WO (1) WO2001054720A1 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20040081655A1 (en) * 2001-01-05 2004-04-29 Karen Lingnau Methods and compositions comprising polycationic compounds
CA2433794A1 (en) 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2418854A1 (en) * 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
JP4188687B2 (en) 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション Immune modulation polynucleotides and methods of use thereof
ES2487645T3 (en) 2001-06-21 2014-08-22 Dynavax Technologies Corporation chimeric immunomodulatory compounds and methods of use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002326561B2 (en) 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
JP2005519990A (en) * 2001-10-12 2005-07-07 コーリー ファーマシューティカル グループ,インコーポレイテッド Methods and products for enhancing the immune response using the imidazoquinoline compound
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CN1662253A (en) * 2002-06-20 2005-08-31 赛托斯生物技术公司 Packaged virus-like particles for use as adjuvants: method of preparation and use
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN100546998C (en) 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 Immunostimulatory sequence oligonucleotides and methods of using the same
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
DK1601770T3 (en) 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigens
WO2004084938A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
JP2007523609A (en) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフトIntercell Ag S. epidermidis antigen
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
CN101864432A (en) 2003-05-07 2010-10-20 英特塞尔股份公司 S. agalactiae antigens I + II
EP1629005A2 (en) 2003-05-30 2006-03-01 Intercell AG Enterococcus antigens
JP4734241B2 (en) * 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフトIntercell Ag Hcv vaccine
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド Compounds for immune enhancement
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2007011776A2 (en) 2005-07-15 2007-01-25 Novartis Ag Pamps, pathogen associated molecular patterns
RU2451523C2 (en) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Particles packed in immunostimulating nucleic acid that intended for hypersensitivity treatment
SI2032592T1 (en) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
JP2009542196A (en) 2006-07-07 2009-12-03 インターセル アーゲー Small S. pyogenes antigens and their use
EP2275434A1 (en) 2006-09-15 2011-01-19 Intercell AG Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
JP5437813B2 (en) 2007-01-12 2014-03-12 インターセル アーゲー S. Agalactiae defense proteins, methods of using the combination, and it
EP2338902A1 (en) 2007-05-02 2011-06-29 Intercell AG Klebsiella antigens
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
JP2010530229A (en) 2007-06-18 2010-09-09 インターセル アーゲー Antigen of Chlamydia
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
DE102007044093A1 (en) * 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nucleic acid-containing cosmetic and / or pharmaceutical preparations for the induction of antimicrobial peptides in epithelial tissues Deck
EP2265634A2 (en) 2008-03-17 2010-12-29 Intercell AG Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
PL2310046T3 (en) 2008-06-27 2016-09-30 Novel adjuvant compositions
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
PE16892012A1 (en) 2009-10-09 2012-12-14 Sanofi Sa Polypeptides for receptor binding for advanced glycation end products as well as compositions and methods involving the same
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
WO2011150249A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
PT2753352T (en) 2010-09-03 2017-03-08 Intercell Usa Inc Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
WO2012158960A2 (en) * 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
CN103702687A (en) * 2011-07-29 2014-04-02 西莱克塔生物科技公司 Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
WO2013113325A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
MX2016003658A (en) 2013-09-19 2016-06-24 Zoetis Services Llc Oil-based adjuvants.
JP2016533352A (en) 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド Treatment with immunostimulatory HIV Tat derivative polypeptide of cancer
EP3129050A2 (en) 2014-04-01 2017-02-15 CureVac AG Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
ES2267100T5 (en) * 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides.
RS50101B (en) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for immunomodulation
ES2241042T3 (en) * 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugates immunostimulatory polynucleotide / immunomodulatory molecule.
WO1998052962A1 (en) * 1997-05-19 1998-11-26 Merck & Co., Inc. Oligonucleotide adjuvant
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE19803453A1 (en) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int vaccine

Also Published As

Publication number Publication date
ES2304376T3 (en) 2008-10-16
UY26555A1 (en) 2001-08-27
US20020197269A1 (en) 2002-12-26
CA2396884A1 (en) 2001-08-02
AR026940A1 (en) 2003-03-05
WO2001054720A1 (en) 2001-08-02
AT409085B (en) 2002-05-27
EP1251871B1 (en) 2008-04-23
JP2003520824A (en) 2003-07-08
ATA1292000A (en) 2001-10-15
DE60133717D1 (en) 2008-06-05
EP1251871A1 (en) 2002-10-30
AU3166501A (en) 2001-08-07
DE60133717T2 (en) 2009-07-02
PE12172001A1 (en) 2001-12-04
AU784403B2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EP1218031B1 (en) Pharmaceutical composition comprising an antigen
DE60027463D1 (en) Pharmaceutical compositions containing resveratrol and uses thereof
RU2006100679A (en) Modified recombinant vaccinated viruses and other microorganisms and their use
RU2003114434A (en) The vaccine composition
DE69923434D1 (en) Adjuvanted recombinant live vaccines against influenza or herpes viruses
DE60238355D1 (en) Suction cup assembly, and displacing means for displacing of the vaccinated eggs
DK1584685T3 (en) A tumor-associated, antigen from the MAGE family, used to prepare fusion proteins with T-helper epitopes and compositions for vaccination
DE60144543D1 (en) Orally administered peptides for alleviating atherosclerosis
AT556719T (en) Vaccine against human influenza, which contains four peptides from influenza
NZ525321A (en) Adjuvant formulations comprising an immunostimulatory oligonucleotide (DNA) and a tocol
DK1151004T3 (en) A process for the preparation of IL-1ra, a therapeutic protein, from body fluids
NO20033384D0 (en) pharmaceutical formulations
RU2006117429A (en) The immunogenic composition and method razorabotki vaccine based on binding sites of factor H
NO20020811L (en) Sulfonylkarboksamidderivater, process for their preparation and their use as medicaments
NO20021542L (en) New <alpha> -aminosyresulfonylforbindelser, process for their preparation and pharmaceutical compositions inneholdendedem
ES2150493T3 (en) Adjuvants for vaccines Respiratory Syncytial Virus.
NO20024175L (en) Azetidine, their preparation and pharmaceutical compositions containing the compounds
NO328498B1 (en) Compounds, pharmaceutical formulations containing them, and use of the compounds for preparing drugs
NO991815D0 (en) Oxadiazoles, fremgangsmÕter for their preparation and their use as medicaments
UY26555A1 (en) pharmaceutical composition for immunomodulation and preparation of vaccines
NO995349D0 (en) Multivalent vaccine composition with mixed berries
AT321569T (en) Combined vaccine compositions
DK1459766T3 (en) Adjuvant for enhancing immune responses to vaccines polynukleotidbaserede
NO330532B1 (en) An immunogenic composition, vaccine prepared therefrom, use as a medicament and method of feeding for preparing
NO336004B1 (en) Specific polypeptides are capable of binding to human Angiopoietin-2, pharmaceutical composition thereof and the use thereof for preparing a medicament.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties